For instance, in a recent paperby Du et al, we demonstrated the use of stimulated Raman spectro-microscopyfor the identification of phenotype-dependent metabolic susceptibilitiesin patient-derived, BRAF mutant melanoma lines with varying levelsof differentiation.152 Mutations in theBRAF gene are known to cause elevated kinase activity, and this genehas been identified as an oncogene in malignant melanoma.153 At the global level, we identified the fattyacid synthesis pathway as a pharmacological target for differentiatedmelanocytic cells. This evidence concerns the gene BRAF and melanoma.